Formosa Pharmaceuticals, Inc. (TPE:6838)

Market Cap	4.13B -19.7%
Revenue (ttm)	12.16M -91.2%
Net Income	-74.25M
EPS	-0.50
Shares Out	150.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,545
Average Volume	302,227
Open	28.45
Previous Close	28.15
Day's Range	27.75 - 28.45
52-Week Range	21.55 - 43.45
Beta	1.00
RSI	43.89
Earnings Date	Mar 12, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6838

Financial Performance

In 2024, Formosa Pharmaceuticals's revenue was 143.36 million, an increase of 359.89% compared to the previous year's 31.17 million. Losses were -201.01 million, -37.56% less than in 2023.